Home » Stocks » ORIC

Oric Pharmaceuticals Inc. (ORIC)

Stock Price: $21.00 USD -0.33 (-1.55%)
Updated Apr 19, 2021 3:36 PM EDT - Market open
Market Cap 782.70M
Revenue (ttm) n/a
Net Income (ttm) -73.70M
Shares Out 21.94M
EPS (ttm) -3.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $21.00
Previous Close $21.33
Change ($) -0.33
Change (%) -1.55%
Day's Open 21.14
Day's Range 20.43 - 21.56
Day's Volume 61,467
52-Week Range 18.60 - 40.81

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH SAN FRANCISCO and SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanism...

1 week ago - GlobeNewsWire

Lead program ORIC-101 on track for two initial data readouts in 2021

3 weeks ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address m...

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address m...

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address me...

2 months ago - GlobeNewsWire

Lead program ORIC-101 continues patient enrollment investigating two therapeutic mechanisms of action and on track for two initial data readouts in 2021

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address me...

3 months ago - GlobeNewsWire

Initiated Part II expansion of the Phase 1b study of ORIC-101 in combination with Abraxane (nab-paclitaxel) using recommended Phase 2 dose selected from Part I of the study

3 months ago - GlobeNewsWire

ORIC Pharmaceuticals (ORIC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

About ORIC

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. Its other product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-9... [Read more...]

Industry
Biotechnology
IPO Date
Apr 24, 2020
CEO
Jacob Chacko
Employees
61
Stock Exchange
NASDAQ
Ticker Symbol
ORIC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for ORIC stock is "Strong Buy." The 12-month stock price forecast is 44.43, which is an increase of 111.57% from the latest price.

Price Target
$44.43
(111.57% upside)
Analyst Consensus: Strong Buy